Načítá se...
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036749/ https://ncbi.nlm.nih.gov/pubmed/31746224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0042 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|